We are live on
!
Find out more
PCML
Pavaki Capital Management LLC Portfolio holdings
AUM
$287M
This Fund
S&P 500
This Quarter
Est. Return
+0.76%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$235M
AUM Growth
-$19.8M
(-7.8%)
Cap. Flow
+$13.6M
Cap. Flow
% of AUM
5.79%
Top 10 Holdings %
Top 10 Hldgs %
50.47%
Holding
162
New
31
Increased
16
Reduced
7
Closed
6
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Chevron
CVX
|
+$13.2M |
| 2 |
iShares MSCI Singapore ETF
EWS
|
+$1.69M |
| 3 |
ESPR
Esperion Therapeutics
ESPR
|
+$1.3M |
| 4 |
B
Barrick Mining
B
|
+$1.27M |
| 5 |
NewAmsterdam Pharma
NAMS
|
+$1.19M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$8.8M |
| 2 |
ARS Pharmaceuticals
SPRY
|
+$5.71M |
| 3 |
Organon & Co
OGN
|
+$3.01M |
| 4 |
Roivant Sciences
ROIV
|
+$868K |
| 5 |
Altimmune
ALT
|
+$778K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 20.32% |
| 2 | Materials | 13.21% |
| 3 | Energy | 8.84% |
| 4 | Technology | 4.85% |
| 5 | Communication Services | 4.71% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Organon & Co
OGN
$3.57B
| $1.97M | 0.83% |
328,100
-400,000
| -55% | -$3.01M |
|
|
PSKY
27
Paramount Skydance Corp
PSKY
$10.3B
| $1.88M | 0.8% |
208,863
| – | – |
|
28
CALL
O'Reilly Automotive
ORLY
$76.3B
| $1.77M | 0.75% |
19,200
| – | – |
|
|
29
iShares MSCI Singapore ETF
EWS
$1.08B
| $1.69M | 0.72% |
+60,000
| New | +$1.69M |
|
30
CALL
AutoZone
AZO
$51.1B
| $1.69M | 0.72% |
500
| – | – |
|
31
Bio-Rad Laboratories Class A
BIO
$9.42B
| $1.67M | 0.71% |
6,000
| – | – |
|
32
Douglas Elliman
DOUG
$162M
| $1.66M | 0.71% |
1,013,752
+200
| +0% | +$464 |
|
33
Kinross Gold
KGC
$32.8B
| $1.51M | 0.64% |
49,500
| – | – |
|
34
CALL
Salesforce
CRM
$158B
| $1.49M | 0.63% |
8,000
| – | – |
|
35
Yum China
YUMC
$16.3B
| $1.46M | 0.62% |
30,000
| – | – |
|
36
Baidu
BIDU
$37.2B
| $1.45M | 0.62% |
13,000
| – | – |
|
37
Equinox Gold
EQX
$13.5B
| $1.45M | 0.61% |
100,000
| – | – |
|
38
Syndax Pharmaceuticals
SNDX
$1.82B
| $1.4M | 0.6% |
60,000
| – | – |
|
39
Sphere Entertainment
SPHR
$5.73B
| $1.39M | 0.59% |
11,860
| – | – |
|
40
PUT
Toll Brothers
TOL
$14.5B
| $1.36M | 0.58% |
10,000
| – | – |
|
41
PUT
Palantir
PLTR
$413B
| $1.32M | 0.56% |
9,000
| – | – |
|
42
iShares MSCI Philippines ETF
EPHE
$145M
| $1.19M | 0.51% |
48,000
+30,000
| +167% | +$781K |
|
|
43
NewAmsterdam Pharma
NAMS
$3.34B
| $1.17M | 0.5% |
+36,600
| New | +$1.19M |
|
|
ESPR
44
DELISTED
Esperion Therapeutics
ESPR
| $1.12M | 0.48% |
+410,000
| New | +$1.3M |
|
45
Hewlett Packard
HPE
$70.5B
| $976K | 0.41% |
41,000
| – | – |
|
46
Banco Bradesco
BBD
$36.7B
| $965K | 0.41% |
264,336
+20,000
| +8% | +$75.8K |
|
47
Sanofi
SNY
$104B
| $964K | 0.41% |
20,000
| – | – |
|
48
Royal Gold
RGLD
$19.5B
| $954K | 0.41% |
3,750
| – | – |
|
49
PUT
Carvana
CVNA
$77.9B
| $943K | 0.4% |
15,000
-30,000
| -67% | -$2.23M |
|
50
CALL
Oracle
ORCL
$423B
| $883K | 0.38% |
6,000
| – | – |
|
Similar funds
GCM
AWM
EA
MAG
PAM
MM
FCG
A
Pavaki Capital Management LLC's Q1 2026 Portfolio in Review
As of Q1 2026, Pavaki Capital Management LLC held 162 positions worth $235M, down 7.8% from $255M the previous quarter. Its ten largest holdings account for 50% of the portfolio.
Pavaki Capital Management LLC deployed $13.6M of net new capital in Q1 2026, opening 31 new positions and adding to 16 existing holdings. Its largest new stake was iShares MSCI Singapore ETF: 60,000 shares worth $1.69M.
By sector, the portfolio is most concentrated in Healthcare at 20% of assets, down from 30% a quarter earlier, followed by Materials and Energy.
On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $8.8M trimmed.
- Pavaki Capital Management LLC's largest Q1 2026 buy was iShares MSCI Singapore ETF: 60,000 shares worth $1.69M.
- Pavaki Capital Management LLC added most to Chevron in Q1 2026, an estimated $13.2M increase.
- Pavaki Capital Management LLC's biggest Q1 2026 reduction was Regeneron Pharmaceuticals, cutting an estimated $8.8M.
- Pavaki Capital Management LLC fully exited Roivant Sciences in Q1 2026, selling an estimated $868K.
- Pavaki Capital Management LLC's ten largest holdings make up 50% of its $235M portfolio in Q1 2026.
- Pavaki Capital Management LLC opened 31 new positions and closed 6 in Q1 2026.
- Pavaki Capital Management LLC's portfolio value fell 7.8% quarter-over-quarter to $235M.
Based on Pavaki Capital Management LLC's 13F filing for Q1 2026, filed 7 Aug 2026.